Comparing prescribing and spending across originator, follow-on, and interchangeable biosimilar insulin glargine: Opportunities to improve uptake of biosimilar medications. [PDF]
Abrams LM, Funk K, Farley JF.
europepmc +1 more source
Biosimilars in diabetic macular edema: Promise, progress, and pitfalls. [PDF]
Jain V +4 more
europepmc +1 more source
Which drugs will Medicare negotiate next? Predicting selected drugs for Initial Price Applicability Year 2029. [PDF]
Li KH, Cousin EM, Sullivan SD.
europepmc +1 more source
Response to "Interpreting bone turnover responses and treatment persistence with once-weekly teriparatide". [PDF]
Gu J, Zhao Q, Zhang X, Zhang Z.
europepmc +1 more source
Real-World Comparison of Biosimilar Ranibizumab (Ranieyes) and Innovator Ranibizumab (Lucentis/Accentrix) Across Multiple Retinal Vascular Diseases (The BRIO Study). [PDF]
Chakraborty D +9 more
europepmc +1 more source
Advances in Biosimilars: A Systematic Review of Machine Learning Applications. [PDF]
Duarte V, Bas TG.
europepmc +1 more source
Real-World Analysis of Switching Between Ranibizumab Biosimilars: Safety and Results - a Multicenter Retrospective Observational Study. [PDF]
Chakraborty D +7 more
europepmc +1 more source
Osteoporosis treatment with biosimilars in Malaysia and Thailand: a budget impact analysis. [PDF]
Siachalinga L +7 more
europepmc +1 more source
Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India. [PDF]
Chakraborty D, Sinha TK, Boral S, Das A.
europepmc +1 more source
A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007). [PDF]
Wang C +10 more
europepmc +1 more source

